Kanoria Chemicals & Industries Limited has informed the Exchange regarding Board meeting held on August 05, 2025.
KANORICHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kanoria Chemicals reported its Q1 FY26 results. Standalone revenue from operations jumped to ₹18,658 lakhs from ₹11,168 lakhs a year ago, a growth of about 67%, driven by higher chemical sales. Standalone operating profit (before depreciation, interest, and tax) rose to ₹1,904 lakhs from ₹871 lakhs, but the company swung to a standalone loss of about ₹505 lakhs after booking a ₹1,064 lakh impairment on its investment in Swiss subsidiary APAG Holding AG. On a consolidated basis, revenue grew roughly 18% YoY to ₹45,378 lakhs, with a net loss of ₹1,378 lakhs, narrower than last year's ₹2,293 lakh loss. The Board approved a plan to dilute its stake in APAG from 55% to about 14.3% by bringing in a strategic investor in two phases, with the second phase expected in FY 2029-30. The Electronic Automotive and Textile segments continue to post losses at the consolidated level.
The strong revenue growth and improvement in operating profit are positive, but the APAG stake dilution, ongoing impairment, and persistent consolidated losses (including losses in the Electronic Automotive and Textile segments) suggest continued pressure on shareholder value. Investors should watch for shareholder approval of the APAG divestment and clarity on the valuation in phase 2.